Organisation paid for research Program year 2023 Source: CMS Open Payments

BioPhase Software Analytics Inc

Neither a doctor nor a teaching hospital

Research payments

$74,084

21 payments

Through program year 2023, BioPhase Software Analytics Inc is reported as receiving $74,084 in research payments, across 21 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2023	Research	$18,178	9
2022	Research	$55,906	12

Breakdown

Who paid Research payments · program years 2022–2023

Arena Pharmaceuticals, Inc. $55,906 12 payments
Teva Pharmaceuticals USA, Inc. $16,678 8 payments
Pfizer Inc. $1,500 1 payment

Studies the money was for Research payments · program years 2022–2023

A Phase 2 Randomized Doubleblind Placebocontrolled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis $57,406 13 payments
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) $16,678 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.